Lääketieteen alalla äärimmäisen meritoitunut tohtoorismies Peter McCullough (on kuulemma kardiologi, epidemiologi ja sisäelinsairauksiin vieläpä erikoistunut ja aivan jumalattomasti vertaisarvioidusti julkaissut ja USA:n liittovaltio- ja osavaltiotasolla lukuisissa lainsäädäntöelimien komiteoissa todistanut jne. jne.) esittelee syyskuussa Toxicology Reports -tiedejournaalissa julkaistun "Why are we vaccinating Children against COVID-19?" (
https://www.sciencedirect.com/science/article/pii/S221475002100161X ) keskeisiä tuloksia.
Artikkelin tuloksiin on päädytty epidemiologiselta kannalta (mutta ei ole edes huomioitu koronan varhaisen lääkityksen mahdollisuutta) ja ne ovat lievästi sanottuna hurjia verrattuna tämänhetkiseen yleiseen käsitykseen koronarokotteiden suhteellisesta hyödystä yli 65-vuotiailla. En ole jaksanut kahlata artikkelia systemaattisesti läpi (ainostaan abstraktin ja vilkuilemalla läpi muuta, muuten olen videon varassa) joten sen rakentava kritiikki otetaan vastaan. Tohtori McCullough on kyllä samaa mieltä artikkelin päättelyketjun ja tulosten kanssa.
https://www.globalresearch.ca/video-the-vaccine-is-more-dangerous-than-covid-19-dr-peter-mccullough/
Video: The Vaccine is More Dangerous than COVID-19: Dr. Peter McCullough
Why are we Vaccinating Children Against COVID-19?
By
Dr. Peter McCullough and
Michael Welch
Global Research, November 06, 2021
Global Research 26 October 2021
Region:
USA,
World
Theme:
Media Disinformation,
Science and Medicine
-----------------
https://www.sciencedirect.com/science/article/pii/S221475002100161X
Why are we vaccinating children against COVID-19?
Author links open overlay panel
Ronald N.Kostoff a
Daniela Calina b Darja Kanduc c Michael B.Briggs d Panayiotis Vlachoyiannopoulos e Andrey A. Svistunov f Aristidis Tsatsakis g
a) Independent Consultant, Gainesville, VA, 20155, USA b) Department of Clinical Pharmacy, University of Medicine and Pharmacy of Craiova, 200349, Craiova, Romania c) Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari, Italy d) Independent Consultant, Roscommon, MI, 48653, USA e) Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece f) Department of Pharmacology, I.M.Sechenov First Moscow State Medical University (Sechenov University), 119146, Moscow, Russia g) Department of Forensic Sciences and Toxicology, Faculty of Medicine, University of Crete, 71003, Heraklion, Greece
Received 16 July 2021, Revised 11 August 2021, Accepted 29 August 2021, Available online 14 September 2021.
Handling Editor: Dr. Konstantinos Poulas
Highlights
• Bulk of COVID-19 per capita deaths occur in elderly with high comorbidities.
• Per capita COVID-19 deaths are negligible in children.
• Clinical trials for these
inoculations were very short-term.
• Clinical trials did not address long-term effects most relevant to children.
• High post-inoculation deaths reported in VAERS (very short-term).
Abstract
This article examines issues related to COVID-19 inoculations for children. The bulk of the official COVID-19-attributed deaths per capita occur in the elderly with high comorbidities, and the COVID-19 attributed deaths per capita are negligible in children. The bulk of the normalized post-inoculation deaths also occur in the elderly with high comorbidities, while the normalized post-inoculation deaths are small, but not negligible, in children. Clinical trials for these inoculations were very short-term (a few months), had samples not representative of the total population, and for adolescents/children, had poor predictive power because of their small size. Further, the clinical trials did not address changes in biomarkers that could serve as early warning indicators of elevated predisposition to serious diseases. Most importantly, the clinical trials did not address long-term effects that, if serious, would be borne by children/adolescents for potentially decades.
A novel
best-case scenario cost-benefit analysis showed
very conservatively that there are five times the number of deaths attributable to each inoculation vs those attributable to COVID-19 in the most vulnerable 65+ demographic. The risk of death from COVID-19 decreases drastically as age decreases, and the longer-term effects of the inoculations on lower age groups will increase their risk-benefit ratio, perhaps substantially.